Toll-like receptors as targets for immune disorders.

Hdl Handle:
http://hdl.handle.net/10147/207802
Title:
Toll-like receptors as targets for immune disorders.
Authors:
Keogh, Brian; Parker, Andrew E
Affiliation:
Opsona Therapeutics Ltd., Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St. James' Hospital, Dublin 8, Ireland. bkeogh@opsona.com
Citation:
Trends Pharmacol Sci. 2011 Jul;32(7):435-42. Epub 2011 Apr 27.
Journal:
Trends in pharmacological sciences
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207802
DOI:
10.1016/j.tips.2011.03.008
PubMed ID:
21529972
Abstract:
Since the identification of the first Toll-like receptor (TLR) in humans in 1997, understanding of the molecular basis for innate immunity has increased significantly. The TLR family and downstream signalling pathways have been extensively characterised, There is now significant evidence suggesting a role for TLRs in human inflammatory and immune diseases such as rheumatoid arthritis, diabetes, allergy/asthma and atherosclerosis. Various approaches have been taken to identify novel therapeutic agents targeting TLRs including biologics, small molecules and nucleic acid-based drugs. Several are now being evaluated in the clinic and showing promise against various diseases. This review paper outlines the recent advances in the understanding of TLR biology and highlights novel TLR agonists and antagonists in development for the treatment of immune diseases.
Language:
eng
MeSH:
Animals; Humans; Immune System Diseases/*immunology/therapy; Immunity, Innate/immunology; Molecular Targeted Therapy; Signal Transduction/immunology; Toll-Like Receptors/*immunology/metabolism
ISSN:
1873-3735 (Electronic); 0165-6147 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKeogh, Brianen_GB
dc.contributor.authorParker, Andrew Een_GB
dc.date.accessioned2012-02-01T10:45:08Z-
dc.date.available2012-02-01T10:45:08Z-
dc.date.issued2012-02-01T10:45:08Z-
dc.identifier.citationTrends Pharmacol Sci. 2011 Jul;32(7):435-42. Epub 2011 Apr 27.en_GB
dc.identifier.issn1873-3735 (Electronic)en_GB
dc.identifier.issn0165-6147 (Linking)en_GB
dc.identifier.pmid21529972en_GB
dc.identifier.doi10.1016/j.tips.2011.03.008en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207802-
dc.description.abstractSince the identification of the first Toll-like receptor (TLR) in humans in 1997, understanding of the molecular basis for innate immunity has increased significantly. The TLR family and downstream signalling pathways have been extensively characterised, There is now significant evidence suggesting a role for TLRs in human inflammatory and immune diseases such as rheumatoid arthritis, diabetes, allergy/asthma and atherosclerosis. Various approaches have been taken to identify novel therapeutic agents targeting TLRs including biologics, small molecules and nucleic acid-based drugs. Several are now being evaluated in the clinic and showing promise against various diseases. This review paper outlines the recent advances in the understanding of TLR biology and highlights novel TLR agonists and antagonists in development for the treatment of immune diseases.en_GB
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmune System Diseases/*immunology/therapyen_GB
dc.subject.meshImmunity, Innate/immunologyen_GB
dc.subject.meshMolecular Targeted Therapyen_GB
dc.subject.meshSignal Transduction/immunologyen_GB
dc.subject.meshToll-Like Receptors/*immunology/metabolismen_GB
dc.titleToll-like receptors as targets for immune disorders.en_GB
dc.contributor.departmentOpsona Therapeutics Ltd., Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St. James' Hospital, Dublin 8, Ireland. bkeogh@opsona.comen_GB
dc.identifier.journalTrends in pharmacological sciencesen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.